摘要目的 观察不同临床分期前列腺癌的抗原提呈路径的表达差异,探讨抗原加工相关转运体1(TAP1)与肿瘤发生及恶性程度相关性.方法 收集前列腺癌、正常前列腺组织以及前列腺增生症(BPH)标本,进行Western blot和免疫组织化学染色,并根据蛋白条带的灰度值和免疫组织化学结果进行定量评分.结果 Western blot显示前列腺癌标本中TAP1表达灰度为0.210±0.093,比较正常前列腺组(0.310±0.021)和BPH组(0.250±0.067),差异有统计学意义(P＜0.05).免疫组织化学显示前列腺癌中TAP1阳性染色评分为(1.200±0.316)分,比较正常前列腺组的(2.600±0.244)分和BPH组的(2.000±0.235)分,差异有统计学意义(P＜0.05),且TAP1表达与前列腺癌的分期和Gleason评分相关.结论 检测TAP1的表达有助于判断前列腺癌的预后.

abstractsObjective To explore the transporter associated with antigen processing 1 (TAP1) expression differences in different clinical staging of prostate cancer.Methods The prostate cancer specimens, the normal prostate tissue and benign prostatic hyperplasia (BPH) specimens were obtained.The TAP1 expression was detected by Western blotting and immunohistochemical staining.According to the results of immunohistochemical staining, the scores were calucated for the analysis of TAP1 expression.Results According to the Western blotting results of TAP1, the TAP1 expression (0.210 ± 0.093) in prostate cancer was lower than that in normal prostate (0.310 ± 0.021) and BPH (0.250 ± 0.067).The TAP1 score of immunohistochemical staining (1.200 ±0.316) in prostate cancer was lower than that in normal prostate (2.600 ± 0.244) and BPH (2.000 ± 0.235).The TAP1 expression was also correlated with tumor stage and Gleason scores.Conclusion Detection of TAP1 expression can provide evidience of prognosis for patients with prostate cancer.